ProfileGDS5678 / 1431612_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 38% 37% 37% 36% 36% 37% 35% 39% 36% 37% 36% 37% 36% 36% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.9069938
GSM967853U87-EV human glioblastoma xenograft - Control 22.8298237
GSM967854U87-EV human glioblastoma xenograft - Control 32.8352637
GSM967855U87-EV human glioblastoma xenograft - Control 42.77236
GSM967856U87-EV human glioblastoma xenograft - Control 52.7729336
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.9150137
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.8395835
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.8706539
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.8020336
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.8203237
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.8195636
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.8052437
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.828136
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.8202436